Aging-Related Tauopathy (ART), also known as Primary Age-Related Tauopathy (PART), is a neurodegenerative condition characterized by the presence of neurofibrillary tangles (NFTs) in the absence of significant amyloid plaques. It represents a distinct pathological entity that lies on a spectrum between normal aging and Alzheimer's disease.[1]
PART was formally recognized as a diagnostic entity in 2014 by consensus criteria developed by an international working group. It explains why some elderly individuals develop significant tau pathology and cognitive impairment without meeting neuropathological criteria for Alzheimer's disease.[2]
Aging-Related Tauopathy represents a unique entity in the spectrum of tauopathies, characterized by neurofibrillary degeneration in the absence of significant amyloid pathology. This condition bridges the gap between normal aging and Alzheimer's disease, explaining cognitive impairment in individuals who lack the classic amyloid plaques of AD.[1:1]
The recognition of PART has important implications for understanding disease mechanisms, biomarker development, and therapeutic strategies, particularly regarding amyloid-targeting therapies that would be ineffective in pure PART patients.
PART affects a significant proportion of the elderly population, with estimates suggesting that 10-25% of cognitively impaired individuals over age 75 may have PART as their primary pathology. This makes PART one of the most common neurodegenerative proteinopathies after Alzheimer's disease, yet it remains relatively understudied compared to AD and other dementias.
The pathological hallmark of PART is the presence of neurofibrillary tangles composed of hyperphosphorylated tau protein, distributed in a pattern similar to early-stage AD but without the widespread neocortical involvement that characterizes full-blown AD. This selective vulnerability of medial temporal lobe structures explains the prominent memory impairment seen in PART patients.
The term "Primary Age-Related Tauopathy" was introduced to describe:[2:1]
PART exists on a pathological continuum with Alzheimer's disease:[3]
This continuum suggests that some cases may represent "incomplete AD" or "AD-resistant" phenotypes.
The tau protein exists as six isoforms in the adult human brain, generated by alternative splicing of the MAPT gene. These isoforms differ in the presence of three or four microtubule-binding repeats (3R or 4R), resulting from inclusion or exclusion of exon 10.[4]
| Isoform | Exon 10 | 3R/4R | Normal Adult Brain |
|---|---|---|---|
| 1N | Included | 4R | ~50% |
| 2N | Included | 4R | ~50% |
| 3N | Included | 4R | ~50% |
| 4R | Excluded | 3R | ~50% |
| 5R | Excluded | 3R | ~50% |
| 6R | Excluded | 3R | ~50% |
In normal adult brain, the 3R:4R tau ratio is approximately 1:1. However, this ratio is altered in different tauopathies:[5]
The balanced 3R/4R ratio in PART suggests:[^6]
Neurofibrillary Tangles (NFTs):
Neuronal Loss:
Amyloid Plaques:
Other Pathologies:
The distribution of NFTs in PART follows a characteristic pattern that distinguishes it from AD:[^7]
| Brain Region | PART | Alzheimer's Disease |
|---|---|---|
| Olfactory bulb | Often spared | Early involvement |
| Entorhinal cortex | Braak I-II | Braak I-II |
| Hippocampus (CA1) | Moderate-severe | Severe |
| Amygdala | Moderate | Severe |
| Neocortex | Usually spared | Severe (late) |
| Brainstem | Moderate | Variable |
| Subcortical nuclei | Moderate | Variable |
The 2014 Montreal consensus criteria established the diagnostic framework for PART:[1:2]
| Category | Criteria |
|---|---|
| Definite PART | Autopsy confirmation: NFTs present, no/minimal amyloid |
| Probable PART | Clinical + biomarker: Cognitive decline + negative amyloid + tau positivity |
| Possible PART | Clinical only: Age >75, cognitive impairment, uncertain biomarkers |
The Montreal criteria integrate emerging biomarkers:[^8]
While PART is not considered a strongly genetic condition like some other tauopathies, several genetic factors influence susceptibility:[^9]
PART typically presents with:[^10]
The cognitive profile of PART reflects the selective vulnerability of medial temporal lobe structures, particularly the hippocampus and entorhinal cortex. Patients typically present with episodic memory deficits that are disproportionate to other cognitive domains in the early stages. Unlike Alzheimer's disease, where visuospatial deficits often emerge early, PART patients usually maintain relatively intact visuospatial abilities until later stages of the disease.
Memory encoding and retrieval deficits are particularly prominent in PART, reflecting the crucial role of the hippocampus in these cognitive processes. Patients may show preserved recognition memory but impaired free recall, a pattern consistent with hippocampal dysfunction. Semantic memory, which depends more on neocortical regions, tends to be better preserved in PART compared to AD.
| Feature | PART | Alzheimer's Disease |
|---|---|---|
| Memory onset | Often later (75+) | Earlier (60-80) |
| Progression | Slower | More rapid |
| Language | Relatively preserved | Progressive impairment |
| Visuospatial | Often preserved | Early impairment |
| Personality | Relatively preserved | Early changes |
In vivo diagnosis of PART remains challenging:[^8]
CSF biomarkers:
Neuroimaging:
Clinical criteria:
PART must be distinguished from:
No specific treatments for PART exist:[^11]
Symptomatic treatments:
Lifestyle interventions:
The recognition of PART has important therapeutic implications:[^12]
Given the overlap with AD, similar prevention strategies may be beneficial:
The study of Aging Related Tauopathy (Part) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Epidemiological trends and cross-country inequalities in the global burden of Alzheimer's disease and other dementias in postmenopausal women from 1990 to 2021. 1990. ↩︎ ↩︎ ↩︎
Global, regional, and national burden of age-related hearing loss and Alzheimer's disease, 1990-2021, with projections to 2040: A global burden of disease study. 1990. ↩︎ ↩︎
The growing burden of Alzheimer's Disease and other dementias in China: Lessons for an aging society. ↩︎
Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration. ↩︎
Platelet concentrate-derived extracellular vesicles promote adult hippocampal neurogenesis. ↩︎